FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb’s Opdivo (nivolumab). The latest approval allows the immunotherapy to be used in adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy as part of a perioperative […]